Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 94Vincristine 91Filgrastim 91Cytarabine 91Methotrexate 90fludarabine phosphate 85Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Mycophenolic Acid 53Cyclosporine 53Whole-Body Irradiation 50Busulfan 47Melphalan 44blinatumomab 43Tacrolimus 42fludarabine 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × forodesine × Clear all
NCT00289562 2012-01-20

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

BioCryst Pharmaceuticals

Phase 1/2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡